Loading clinical trials...

UNKNOWNNA

A Prehabilitation Program to Boost Postoperative Functional Capacity in Surgical Lung Cancer Patients

A Prehabilitation Program to Boost Postoperative Functional Capacity in Surgical Lung Cancer Patients: a Randomized Controlled Trial

NCT04826835•The University of Hong Kong

View on ClinicalTrials.gov

Summary

This research study is evaluating a prehabiliation intervention designed to improve postoperative functional capacity (measured by 6-minure walking distance) in individuals undergoing lung resection for cancer.

Eligibility

Age

45 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients who are diagnosed of stage I, II, or IIIA Non-small-cell lung carcinoma (NSCLC) diagnosis, with or without pre-operative histologic confirmation
•2. Patients scheduled to undergo lung resection surgery at least two weeks from recruitment
•3. Patients with a Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 at recruitment
•4. Patients with no evidence of recurrent or progressive disease
•5. Patients aged 45-80 years
•6. Patients able to communicate in Cantonese, Mandarin, or English
•7. Patients is absence of any cognitive impairment
•8. Patients with a score of 6 minutes walking test (6MWT) ≤ 500 meters at baseline. \[rationale: a threshold value of 500 meters preoperative 6MWT predicts a higher risk of postoperative complications and prolonged LOS after lung resection\]
•9. Engagement in less than 150 minutes of moderate aerobic activity per week in the past 3 months

Exclusion Criteria

•1. Patients who had engaged in at least 150 minutes of moderate aerobic activity or 75 minutes of vigorous aerobic activity per week in the past three months
•2. Presence of another concurrent, actively treated malignancy
•3. Presence of chronic obstructive pulmonary disease
•4. Presence of significant comorbidities that impede ability to engage in exercise, such as congestive heart failure, orthopedic disorders of the lower limbs, respiratory failure, or the need for portable oxygen therapy for activities of daily living
•5. Not having a smart device to receive WhatsApp messages

Locations (1)

Queen Mary Hospital

Hong Kong, Hong Kong

Key Dates

Start Date

May 14, 2021

Primary Completion Date

May 1, 2025

Completion Date

June 1, 2025

Last Updated

January 8, 2024

Enrollment

198

ESTIMATED participants

Conditions

Lung Cancer

Interventions

Prehabilitation intervention

BEHAVIORAL

Health education control

BEHAVIORAL

Contacts

Chia-chin Lin, PhD

CONTACT

39176614 cclin@hku.hk

Xinyi Xu, BSN

CONTACT

39176948 xuxinyi@connect.hku.hk

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

RECRUITING

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Prehabilitation Program to Boost Postoperative Functional Capacity in Surgical Lung Cancer Patients

Inclusion Criteria

Exclusion Criteria

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Magnetic Resonance Imaging of the Lung: Oncological Applications

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)